TY - JOUR
T1 - Racial disparities in survival in malignant germ cell tumors of the ovary
AU - Hinchcliff, Emily
AU - Rauh-Hain, J. Alejandro
AU - Clemmer, Joel T.
AU - Diver, Elisabeth
AU - Hall, Tracilyn
AU - Stall, Jennifer
AU - Growdon, Whitfield
AU - Clark, Rachel
AU - Schorge, John
N1 - Publisher Copyright:
© 2016 Elsevier Inc. All rights reserved.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - Objective To investigate racial disparities with respect to adjuvant treatment and survival in patients presenting with malignant ovarian germ cell tumors (OGCT). Methods The National Cancer Database (NCDB) was used to identify women diagnosed with OGCT. Demographic data were abstracted, including stratification by race and histology. Standard univariate and multivariate analyses using logistic regression were performed to describe predictors of adjuvant treatment. Kaplan-Meier and Cox proportional hazards survival methods were used to evaluate racial differences in survival between African American (AA) and white (W) women. Results The study population included 2196 patients, with 1654 (75.3%) W and 328 (14.9%) AA women. Histologic distribution varied significantly by race (p < 0.0001), but neither age nor stage at presentation showed racial differences (p = 0.086 and p = 0.209, respectively). AA received more chemotherapy than W (W: 54.6%, AA: 65.5%, p = 0.008), but in multivariate analysis there was no statistically significant difference in any adjuvant treatment modality. Despite similar treatment, and independent of histology, survival varied significantly by race with 91% (CI 0.89-0.93) five year survival in W patients compared to 84% five year survival in AA (CI 0.8-0.89) (p = 0.02). These disparities were most pronounced in advanced stage disease, with 5 year survival of 84% (CI 0.79-0.89) in W compared to 61% (CI 0.48-0.78) for AA in stage III (p = 0.0002), and 54% (CI 0.42-0.68) compared to 14% (CI 0.03-0.71) for stage IV (p = 0.05). Conclusions AA with OGCT have significantly worse 5 year survival when compared to W patients despite similar rates and modalities of adjuvant treatment.
AB - Objective To investigate racial disparities with respect to adjuvant treatment and survival in patients presenting with malignant ovarian germ cell tumors (OGCT). Methods The National Cancer Database (NCDB) was used to identify women diagnosed with OGCT. Demographic data were abstracted, including stratification by race and histology. Standard univariate and multivariate analyses using logistic regression were performed to describe predictors of adjuvant treatment. Kaplan-Meier and Cox proportional hazards survival methods were used to evaluate racial differences in survival between African American (AA) and white (W) women. Results The study population included 2196 patients, with 1654 (75.3%) W and 328 (14.9%) AA women. Histologic distribution varied significantly by race (p < 0.0001), but neither age nor stage at presentation showed racial differences (p = 0.086 and p = 0.209, respectively). AA received more chemotherapy than W (W: 54.6%, AA: 65.5%, p = 0.008), but in multivariate analysis there was no statistically significant difference in any adjuvant treatment modality. Despite similar treatment, and independent of histology, survival varied significantly by race with 91% (CI 0.89-0.93) five year survival in W patients compared to 84% five year survival in AA (CI 0.8-0.89) (p = 0.02). These disparities were most pronounced in advanced stage disease, with 5 year survival of 84% (CI 0.79-0.89) in W compared to 61% (CI 0.48-0.78) for AA in stage III (p = 0.0002), and 54% (CI 0.42-0.68) compared to 14% (CI 0.03-0.71) for stage IV (p = 0.05). Conclusions AA with OGCT have significantly worse 5 year survival when compared to W patients despite similar rates and modalities of adjuvant treatment.
KW - Ovarian cancer
KW - Ovarian germ cell tumors
KW - Racial disparities
KW - Rare tumors
UR - http://www.scopus.com/inward/record.url?scp=84959527357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959527357&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2016.01.006
DO - 10.1016/j.ygyno.2016.01.006
M3 - Article
C2 - 26773470
AN - SCOPUS:84959527357
SN - 0090-8258
VL - 140
SP - 463
EP - 469
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 3
ER -